Xbrane In Negotiations For Nivolumab Candidate As It Gets More Time On Deal
Swedish Developer Is ‘Optimistic’ A Deal Can Be Closed By The End Of Next Month
Xbrane Biopharma is on the clock to bring in a licensing partner for one of its two biosimilar candidates in order to fulfil its short-term working capital requirements. The Swedish firm has revealed that a deal for one appears close, as it also reached an agreement for more time to put pen to paper.
